Please login to the form below

Not currently logged in
Email:
Password:

Voltarra names new CEO

Richard Becker has experience at Alcon, Merck, Novartis, OSI, Bayer and BASF

Voltarra Pharmaceuticals has appointed Richard Becker as CEO.

Becker brings more than 20 years' experience to the US biopharma, including senior commercial roles at Alcon, Merck, Novartis, OSI, Bayer and BASF.

In his new role, he leads a company with a pipeline of drugs for rheumatology, central nervous system oncology and immunology.

Voltarra's lead product is VOLT01, which is in late-stage trials for the treatment of osteoarthritis.

Becker said: “The broad portfolio will allow Voltarra Pharmaceuticals to capitalise on development synergies and favourably position the company with external customers. We are extremely excited about the pipeline as well as future plans for a partner in taking VOLT01 to the next stage.”

19th November 2013

From: Sales

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics